Development of third generation anti-EGFRvIII chimeric T cells and EGFRvIII-expressing artificial antigen presenting cells for adoptive cell therapy for glioma

Bioactivity and Safety of IL13R 2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma

(2015) C. E. Brown et al.   CLINICAL CANCER RESEARCH

Smart CARs engineered for cancer immunotherapy

(2015) Saul J. Priceman et al.   CURRENT OPINION IN ONCOLOGY

Antibody-modified T cells: CARs take the front seat for hematologic malignancies

(2014) M. V. Maus et al.   BLOOD

EGFRvIII mCAR-Modified T-Cell Therapy Cures Mice with Established Intracerebral Glioma and Generates Host Immunity against Tumor-Antigen Loss

(2013) J. H. Sampson et al.   CLINICAL CANCER RESEARCH

Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies

(2013) Marco L. Davila et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Blocking the interleukin 2 (IL2)-induced systemic autophagic syndrome promotes profound antitumor effects and limits toxicity

(2012) Michael T. Lotze et al.   Autophagy

Recognition of Glioma Stem Cells by Genetically Modified T Cells Targeting EGFRvIII and Development of Adoptive Cell Therapy for Glioma

(2012) Richard A. Morgan et al.   HUMAN GENE THERAPY

Dual Targeting of ErbB2 and MUC1 in Breast Cancer Using Chimeric Antigen Receptors Engineered to Provide Complementary Signaling

(2012) Scott Wilkie et al.   JOURNAL OF CLINICAL IMMUNOLOGY

Comparison of Different Suicide-Gene Strategies for the Safety Improvement of Genetically Manipulated T Cells

(2012) Virna Marin et al.   Human Gene Therapy Methods

OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4+T cells

(2012) Andreas A. Hombach et al.   OncoImmunology

In Vivo Persistence, Tumor Localization, and Antitumor Activity of CAR-Engineered T Cells Is Enhanced by Costimulatory Signaling through CD137 (4-1BB)

(2011) D.-G. Song et al.   CANCER RESEARCH

Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy

(2011) Carlos A Ramos et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Costimulation by chimeric antigen receptors revisited the T cell antitumor response benefits from combined CD28-OX40 signalling

(2011) Andreas A. Hombach et al.   INTERNATIONAL JOURNAL OF CANCER

CD28 costimulation improves expansion and persistence of chimeric antigen receptor–modified T cells in lymphoma patients

(2011) Barbara Savoldo et al.   JOURNAL OF CLINICAL INVESTIGATION

Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy

(2011) Antonio Di Stasi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Antitransgene Rejection Responses Contribute to Attenuated Persistence of Adoptively Transferred CD20/CD19-Specific Chimeric Antigen Receptor Redirected T Cells in Humans

(2010) Michael C. Jensen et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Retrovirally engineered T-cell-based immunotherapy targeting type III variant epidermal growth factor receptor, a glioma-associated antigen

(2010) Masasuke Ohno et al.   CANCER SCIENCE

HER2-Specific T Cells Target Primary Glioblastoma Stem Cells and Induce Regression of Autologous Experimental Tumors

(2010) N. Ahmed et al.   CLINICAL CANCER RESEARCH

Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2

(2010) Richard A Morgan et al.   MOLECULAR THERAPY

Immunotherapy of Metastatic Melanoma Using Genetically Engineered GD2-Specific T cells

(2009) E. Yvon et al.   CLINICAL CANCER RESEARCH

Retroviral transfer of human CD20 as a suicide gene for adoptive T-cell therapy

(2009) M. Griffioen et al.   HAEMATOLOGICA

Genetically engineered T cells to target EGFRvIII expressing glioblastoma

(2009) Szofia S. Bullain et al.   JOURNAL OF NEURO-ONCOLOGY

An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme

(2009) J. H. Sampson et al.   MOLECULAR CANCER THERAPEUTICS

Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells

(2008) B. G. Till et al.   BLOOD